https://www.live-feeds.com/feed/glp-1-injections-recalled-nationwide-over-sterility-concerns-fda-saysContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/glp-1-injections-recalled-nationwide-over-sterility-concerns-fda-sayshttps://www.live-feeds.com/feed/glp-1-injections-recalled-nationwide-over-sterility-concerns-fda-says#u158456Tue, 27 Oct 2026 14:47:09 +0000Federal health regulators announced a nationwide recall for compounded GLP-1 tirzepatide and NAD+ injections distributed by Apothecary Pharma. The Food and Drug Administration flagged the products because their sterility cannot be assured, prompting a Class II risk classification for the medication. Patients across the United States are urged to check specific lot numbers and expiration dates to determine if their weight-loss treatment is affected. The action follows prior warnings issued to the company regarding its manufacturing practices.Why it mattersCompounded versions of popular weight-l